SMS Pharmaceuticals has received revised rating from credit rating agency, CARE. The rating agency has revised BBB+ rating from A- earlier for Rs 171 crore long term bank facilities of the company. The rating agency has also revised the company’s short term bank facilities worth Rs 47.56 crore to A3 from A2.
The company has received the said rating due to deterioration in sales and profitability margins during FY12 coupled with stoppage in receipt of regulatory approvals for its new units.
SMS Pharmaceuticals is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and its intermediates. The company has six manufacturing facilities and two R&D facilities located in Andhra Pradesh.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: